Home › Johnson & Johnson licenses Vedanta's bowel disease drug
 

Keywords :   


Johnson & Johnson licenses Vedanta's bowel disease drug

2015-01-13 15:05:06| Biotech - Topix.net

Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body. J&J's Janssen Pharmaceutical Companies unit says Vedanta Biosciences of Boston could receive up to $241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel disease such as ulcerative colitis or Crohn's disease.

Tags: drug disease johnson licenses

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
01.07Union expected to call off Port Talbot strike action
01.07Mentorship in Motion
01.07Farm Progress America, July 1, 2024
01.07Hurricane Beryl Forecast Discussion Number 11
01.07Hurricane Beryl Graphics
01.07Hurricane Beryl Wind Speed Probabilities Number 11
01.07Hurricane Beryl Forecast Advisory Number 11
01.07Hurricane Beryl Public Advisory Number 11
More »